Business Wire

AGRIF

5.4.2017 12:20:52 CEST | Business Wire | Press release

Share
Incofin Investment Management Partners with New Investors to Increase Access to Financial Services for Smallholder Farmers

Launched in 2015, the agRIF fund seeks to address the scarcity of financial services adapted to the needs of smallholder farmers, an economic segment representing the largest portion of those living on less than $2 per day. It does this by investing equity in financial intermediaries that target the agricultural sector. Initial investors in the fund include the European Investment Bank (EIB), Proparco, the Swiss Investment Fund for Emerging Markets (SIFEM), the Belgische Investeringsmaatschappij voor Ontwikkelingslanden (BIO), Volksvermogen, ACV-CSC Metea, and Incofin Investment Management.

agRIF is a third generation fund, following on Rural Impulse Fund I and Rural Impulse Fund II, which also used closed-ended, leveraged private equity structures to support investments in financial inclusion for the rural sector. agRIF takes this model one step further by specifically targeting the agricultural sector and smallholder farmers, as well as rural micro-entrepreneurs. In addition to the equity investments targeted by the fund, agRIF provides debt investments in agricultural SMEs and agricultural focused financial intermediaries.

Since the first close, new investors such as AXA Investment Managers, KBC Pensioenfonds, Korys, Invest in Visions Global Social Impact Fund, and Maatschappij voor Roerend Bezit van de Boerenbond have committed 27 M USD in equity to support the mission and vision of the Fund.

To date, agRIF has invested 34 M USD in agricultural and rural focused institutions in Latin America, Africa and Asia. The final close of the fund will be in June 2017.

“At Incofin IM, we very much welcome the entry of new first class investors in the Fund, as they enable the fund to enhance its outreach and achieve its highly relevant goals. The new investors decided to subscribe to agRIF because they value our entrepreneurial approach and our strong track record in private equity. Incofin has always been excellent in identifying promising entrepreneurs and in growing their impact business”, says Loïc De Cannière, CEO of Incofin Investment Management.

“The development of the agri-food sector in developing countries is an important investment theme for MRBB,” says Marc Wittemans, CEO of Maatschappij voor Roerend Bezit van de Boerenbond. “MRBB has already invested in Impulse Micro Finance Investment Fund, Rural Impulse Fund, Incofin cvso and recently in AgriF. MRBB is convinced of the competence and integrity of Incofin Investment Management to manage such funds and to achieve a sustainable social and financial return.”

About AXA Investment Managers

AXA Investment Managers is an active, long-term, global, multi-asset investor focused on enabling more people to harness the power of investing to meeting their financial goals. By combining investment insight and innovation with robust risk monitoring, it has become one of the largest asset managers in Europe with ambitions to become the chosen investment partner of investors around the world. With approximately €717bn in assets under management as of end December 2016, AXA IM employs over 2,350 people around the world and operates out of 29 offices in 21 countries. AXA IM is part of the AXA Group, a global leader in financial protection and wealth management.

About Korys

Korys is a family owned holding with a focus on sustainable investments. Today, it has about 4 billion euros assets under management. The company has private equity and also liquid investment activities. Investments are made with a long-term horizon in mind and selected on the basis of economic, ecological and social merit. Korys has multiple participations in the consumer goods and retail business, in renewable energy and in life sciences companies. Korys has offices in Belgium and Luxemburg.

About Invest in Visions Global Social Impact Fonds

Invest in Visions Global Social Impact Fonds aims at investing in economically viable social businesses that pursue achieving a double-bottom line: besides a financial return, invested companies generate a social and / or ecological return. The Fund holds currently 20m Assets under Management and is open to institutional investors seeking competitive market returns whilst generating a benefit for society. Target sectors comprise renewable energy, agriculture, and healthcare among others.

About Maatschappij voor Roerend Bezit van de Boerenbond

MRBB is the investment company of the group Boerenbond and has investments in companies operating in the agri-food chain (supply and services to the agribusiness, commercialization of agricultural products, new technologies such as smart farming, sustainable farming and biobased farming) and in the financial sector.

About Incofin Investment Management

Incofin IM is an impact investor that believes that local entrepreneurship and investments rooted in people's reality create the best conditions for sustainable progress in developing economies. Incofin implements this vision through equity stakes in financial intermediaries focused on the agriculture sector and/or rural markets in emerging economies. It works with its investees to build a more inclusive local financial sector by scaling operations, developing innovative products, improving processes, and supporting best practices in corporate governance. In addition to equity, Incofin also provides direct lending to financial intermediaries, producer organizations and SMEs in the agriculture value chain. Incofin is headquartered in Antwerp, Belgium and has ~50 staff working out of the Antwerp and the regional offices located in Bogota, Colombia; Chennai, India; Nairobi, Kenya; and Phnom Penh, Cambodia.

Contact:

Incofin Investment Management
Dana Roelofs, T +41 77 480 30 98
Business Development Manager
Dana.roelofs@incofin.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye